Cade I S, McEwen J B
Clin Radiol. 1978 May;29(3):333-8. doi: 10.1016/s0009-9260(78)80081-6.
For 12 years randomised clinical trials have been run at Portsmouth in collaboration with the Medical Research Council's Working Party on radiotherapy and high pressure oxygen to determine the survival rate of patients treated by megavoltage radiotherapy in high pressure oxygen (HPO) compared with those treated in air at atmospheric pressure. Five hundred and five patients have been included, 280 with carcinoma bronchus, 163 with carcinoma bladder and 62 with carcinoma cervix stage III. With conventional small fraction daily radiotherapy, the use of HPO has not improved survival in carcinoma of the bronchus and of the bladder. When six fractions of 600 rad maximum tissue dose are given in HPO, some improved survival is shown in carcinoma of the bronchus and of the cervix compared with the same dose in the air series. In the cervix, the survival rate in HPO is almost the same as that of a retrospective series treated by an intrauterine radium tube followed by 6000 rad central depth dose to the whole true pelvis in air. Large fraction radiotherapy has not given improved survival when using adjuvant HPO in carcinoma of the bladder. The bladder trial has now been abandoned.
在过去的12年里，朴茨茅斯与医学研究理事会放射治疗和高压氧工作组合作开展了随机临床试验，以确定接受高压氧（HPO）下兆伏级放射治疗的患者与在常压空气中接受治疗的患者的生存率。共纳入了505例患者，其中280例为支气管癌，163例为膀胱癌，62例为III期宫颈癌。对于常规的每日小剂量分割放射治疗，使用HPO并未提高支气管癌和膀胱癌患者的生存率。当在HPO中给予最大组织剂量600拉德的六次分割照射时，与在空气中给予相同剂量相比，支气管癌和宫颈癌患者的生存率有所提高。在宫颈癌患者中，HPO下的生存率与采用宫腔镭管治疗、随后在空气中对整个真骨盆给予6000拉德中心深度剂量的回顾性系列研究的生存率几乎相同。在膀胱癌患者中，使用辅助性HPO进行大分割放射治疗并未提高生存率。目前，膀胱癌试验已被放弃。
